OCV Partners is a Los Angeles based venture capital firm that invests in companies with differentiated technologies in compelling target markets.
With our decades of company-building experience, our overriding objective is to use our unique expertise to identify or create an asymmetric advantage when backing winning teams.
Our core focus sectors are Technology (SaaS, FinTech, and PropTech) and Healthcare (Healthcare SaaS, Digital Health, MedTech, and Therapeutics).

We are former Founders with a track record of success

We aim to create asymmetric advantages for our Founders

We are flexible capital – we like to lead, but it is not a requirement
Focus Sector: Technology
We invest in brilliant teams building disruptive technology. As former Founders, we have grown businesses from the earliest stages to IPOs and beyond. We invest in:
- Subscription software where we have expertise in growing and acquiring over 165 unique software companies
- Recurring revenue business models where our past experience reveals an asymmetric advantage
- SaaS, Fintech, and PropTech, which are areas where we have previously built companies
Focus Sector: Healthcare
We are scientists and healthcare entrepreneurs who love partnering with Founders building companies that need to exist.
We believe our investments should be challenging and changing what is possible for human health and disease.
We focus on entrepreneurs building disruptive platforms in Healthcare SaaS, Digital Health, MedTech, and Therapeutics.
We invest in companies that:
- Enable precision or targeted approaches to improve patient lives
- Empower better treatment decisions and optimize workflows
- Remove barriers to care and improve equitable access
- Expedite the discovery of new treatments
Our deep technical and operational expertise uniquely positions us to invest in and support startups at the intersection of healthcare and technology.
News
TORL BioTherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology Biologics
Co-founded by acclaimed oncologist Dennis Slamon, M.D., Ph.D., of University of California at Los Angeles (UCLA) and entrepreneur and CEO David Licata, as well as leadership from a distinguished set of industry veterans, including Executive Chairman Mark Alles, former...
ByHeart Acquires Additional Domestic Infant Formula Manufacturing Facility Tripling its Supply Capacity and Continuing to Fortify Formula Production in the U.S.
ByHeart is positioned to reliably and safely meet the needs of families across the country and fully reopen to customers in Q2 of 2023 with an eye toward retail expansion this year The acquisition and pending FDA registration of this manufacturing facility, together...
ByHeart To Acquire Packaging Company Cascadia Nutrition
Acquisition of Packaging Facility Will Complete ByHeart's Ownership of Its End-To-End Manufacturing Process With this Acquisition, ByHeart Will Establish the first New Dedicated Infant Formula Packaging Facility in the Country to Supply the U.S. market in Over 20...
TORL BioTherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology Biologics
Co-founded by acclaimed oncologist Dennis Slamon, M.D., Ph.D., of University of California at Los Angeles (UCLA) and entrepreneur and CEO David Licata, as well as leadership from a distinguished set of industry veterans, including Executive Chairman Mark Alles, former...
ByHeart Acquires Additional Domestic Infant Formula Manufacturing Facility Tripling its Supply Capacity and Continuing to Fortify Formula Production in the U.S.
ByHeart is positioned to reliably and safely meet the needs of families across the country and fully reopen to customers in Q2 of 2023 with an eye toward retail expansion this year The acquisition and pending FDA registration of this manufacturing facility, together...
With our decades of company building experience, we look to create asymmetric advantages when backing winning teams.